Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Cells ; 9(6)2020 06 23.
Artigo em Inglês | MEDLINE | ID: mdl-32585865

RESUMO

BACKGROUND: The earliest manifestation of alcohol-related liver disease (ALD) is steatosis, characterized by the accumulation of lipid droplets (LDs) in hepatocytes. Findings from our laboratory have indicated that many pathological changes, including steatosis, correlate with the alcohol-induced hepatocellular increases in S-adenosylhomocysteine (SAH). Based on these considerations, we hypothesized that an experimental increase in intracellular SAH alone will result in similar steatotic changes to those seen after alcohol exposure. METHODS: Freshly isolated rat hepatocytes grown on collagen-coated plates were exposed to serum-free medium containing 50 µmol/L oleic acid and varying concentrations of 3-deazaadenosine (DZA) to experimentally elevate intracellular SAH levels. RESULTS: Overnight exposure to DZA treatment dose-dependently increased hepatocellular triglyceride accumulation, which was also evident by morphological visualization of larger-sized LDs. The rise in triglycerides and LDs accompanied increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size. Furthermore, DZA treatment caused a decline in the levels of lipases that prevent fat accumulation as well as increased the expression of factors involved in lipogenesis and fatty acid mobilization. Collectively, our results indicate that the elevation of intracellular SAH is sufficient to promote fat accumulation in hepatocytes, which is similar to that seen after alcohol exposure.


Assuntos
Antibióticos Antineoplásicos/uso terapêutico , Etanol/efeitos adversos , Metabolismo dos Lipídeos/efeitos dos fármacos , Hepatopatias/sangue , Hepatopatias/etiologia , S-Adenosil-Homocisteína/efeitos adversos , Tubercidina/uso terapêutico , Animais , Antibióticos Antineoplásicos/farmacologia , Humanos , Hepatopatias/patologia , Masculino , Ratos , Ratos Wistar , Tubercidina/farmacologia
2.
PLoS One ; 8(10): e76900, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24130807

RESUMO

The methyltransferase enzyme (MTase), which catalyzes the transfer of a methyl group from S-adenosyl-methionine (AdoMet) to viral RNA, and generates S-adenosyl-homocysteine (AdoHcy) as a by-product, is essential for the life cycle of many significant human pathogen flaviviruses. Here we investigated inhibition of the flavivirus MTase by several AdoHcy-derivatives. Unexpectedly we found that AdoHcy itself barely inhibits the flavivirus MTase activities, even at high concentrations. AdoHcy was also shown to not inhibit virus growth in cell-culture. Binding studies confirmed that AdoHcy has a much lower binding affinity for the MTase than either the AdoMet co-factor, or the natural AdoMet analog inhibitor sinefungin (SIN). While AdoMet is a positively charged molecule, SIN is similar to AdoHcy in being uncharged, and only has an additional amine group that can make extra electrostatic contacts with the MTase. Molecular Mechanics Poisson-Boltzmann Sovation Area analysis on AdoHcy and SIN binding to the MTase suggests that the stronger binding of SIN may not be directly due to interactions of this amine group, but due to distributed differences in SIN binding resulting from its presence. The results suggest that better MTase inhibitors could be designed by using SIN as a scaffold rather than AdoHcy.


Assuntos
Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacologia , Flavivirus/enzimologia , Metiltransferases/antagonistas & inibidores , Metiltransferases/metabolismo , S-Adenosil-Homocisteína/metabolismo , S-Adenosil-Homocisteína/farmacologia , Adenosina/análogos & derivados , Adenosina/farmacologia , Linhagem Celular , Inibidores Enzimáticos/efeitos adversos , Flavivirus/efeitos dos fármacos , Humanos , Modelos Moleculares , Ligação Proteica , Conformação Proteica , S-Adenosil-Homocisteína/efeitos adversos , Vírus do Nilo Ocidental/efeitos dos fármacos , Vírus do Nilo Ocidental/enzimologia
3.
Int J Oncol ; 22(3): 499-508, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12579301

RESUMO

A novel mechanistic hypothesis is proposed which suggests that hyperhomocysteinemia is a risk factor for the development of estrogen-induced hormonal cancer in humans. Mechanistically, hyperhomocysteinemia may exert its pathogenic effects largely through metabolic accumulation of intracellular S-adenosyl-L-homocysteine, a strong non-competitive inhibitor of the catechol-O-methyltransferase-mediated methylation metabolism of endogenous and exogenous catechol estrogens (mainly 2-hydroxyestradiol and 4-hydroxyestradiol). While a strong inhibition of the methylation metabolism of 2-hydroxyestradiol would decrease the formation of 2-methoxyestradiol (an antitumorigenic endogenous metabolite of 17beta-estradiol), an inhibition of the methylation of 4-hydroxyestradiol would lead to accumulation of this hormonally-active and strongly procarcinogenic catechol estrogen metabolite. Both of these effects resulting from inhibition of the methylation metabolism of catechol estrogens would facilitate the development of estrogen-induced hormonal cancer in the target organs. This hypothesis also predicts that adequate dietary intake of folate, vitamin B6, and vitamin B12 may reduce hyperhomocysteinemia-associated risk for hormonal cancer. Experimental studies are warranted to determine the relations of hyperhomocysteinemia with the altered circulating or tissue levels of 4-hydroxyestradiol and 2-methoxyestradiol and also with the altered risk for estrogen-induced hormonal cancer.


Assuntos
Neoplasias da Mama/epidemiologia , Estradiol/análogos & derivados , Estrogênios , Hiper-Homocisteinemia/epidemiologia , Neoplasias Hormônio-Dependentes/epidemiologia , Neoplasias Uterinas/epidemiologia , Anticarcinógenos/farmacologia , Anticarcinógenos/uso terapêutico , Neoplasias da Mama/prevenção & controle , Catecol O-Metiltransferase/fisiologia , Inibidores de Catecol O-Metiltransferase , Estradiol/metabolismo , Estrogênios/toxicidade , Estrogênios de Catecol/metabolismo , Feminino , Ácido Fólico/farmacologia , Ácido Fólico/uso terapêutico , Humanos , Cinética , Metilação/efeitos dos fármacos , Modelos Biológicos , Testes de Mutagenicidade , Neoplasias Experimentais/induzido quimicamente , Neoplasias Hormônio-Dependentes/prevenção & controle , Fatores de Risco , S-Adenosil-Homocisteína/efeitos adversos , S-Adenosil-Homocisteína/metabolismo , Neoplasias Uterinas/prevenção & controle , Vitamina B 12/farmacologia , Vitamina B 12/uso terapêutico , Vitamina B 6/farmacologia , Vitamina B 6/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA